🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Jefferies Group’s SMMT Holdings & Trades

First Buy
Q4 2024
Duration Held
5 Quarters
Largest Add
Q4 2025
+85,000 Shares
Current Position
100,000 Shares
$1.9 M Value

Jefferies Group's SMMT Position Overview

Jefferies Group (via Jefferies Financial Group Inc.) currently holds 100,000 shares of Summit Therapeutics Inc. (SMMT) worth $1.9 M, representing 0.01% of the portfolio. First purchased in 2024-Q4, this short-term holding has been held for 5 quarters.

Based on 13F filings, Jefferies Group has maintained this position in SMMT for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 85,000 shares. Largest reduction occurred in Q1 2025, reducing 45,001 shares.

Analysis based on 13F filings available since 2013 Q2

Jefferies Group's Summit Therapeutics (SMMT) Holding Value Over Time

Track share changes against reported price movement

Quarterly Summit Therapeutics (SMMT) Trades by Jefferies Group

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +85,000 Add 566.67% 100,000 $17.49
Q3 2025 +15,000 New Buy 15,000 $20.66
Q1 2025 -45,001 Sold Out 0 $0.00
Q4 2024 +45,001 New Buy 45,001 $17.85

Jefferies Group's Summit Therapeutics Investment FAQs

Jefferies Group first purchased Summit Therapeutics Inc. (SMMT) in Q4 2024, acquiring 45,001 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Jefferies Group has held Summit Therapeutics Inc. (SMMT) for 5 quarters since Q4 2024.

Jefferies Group's largest addition to Summit Therapeutics Inc. (SMMT) was in Q4 2025, adding 100,000 shares worth $1.75 M.

According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 100,000 shares of Summit Therapeutics Inc. (SMMT), valued at approximately $1.9 M.

As of the Q1 2026 filing, Summit Therapeutics Inc. (SMMT) represents approximately 0.01% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.

Jefferies Group's peak holding in Summit Therapeutics Inc. (SMMT) was 100,000 shares, as reported at the end of Q4 2025.